NEWSROOM
Press Releases by Agendia
News
Press Releases
New Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint
The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendiaโs advanced genomic assays.
Read MoreAgendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the companyโs Board of Directors.
Read MoreAgendia Studies Reveal the Influence of Race on a Tumorโs Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, reinforces its commitment to progressing research of racial disparities in breast cancer through two poster presentations.
Read MoreAgendia Research Shows Highest Risk MammaPrintยฎ Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer.
Read MoreAgendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendiaโs progress in developing practice-changing evidence to improve personalized cancer care Read More
Updated NCCNยฎ Guidelines Recognize MammaPrintยฎ UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapyยน and endocrine therapyยฒ Con๏ฌrms Agendiaโs unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More
Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrintโs ability to identify strongest candidates for extended endocrine therapy among HR+HER2- post-menopausal women December 08, 2022 09:00 AM Eastern Standard Time Read More
